Blog

Hepatocellular carcinoma (HCC) is a pressing public health concern in the Asia-Pacific region, where over 80% of the world's HCC cases are found. This staggering statistic is driven by high rates of chronic viral hepatitis B and the increasing prevalence of metabolic risk factors, making the APAC region a global hotspot for HCC.

'By embracing technology and leveraging data-driven insights, we are looking forward to this engagement to optimize efficiency, improve outcomes, and enhance the patient experience,' said Dr Mohana Vamsy.

In this post, we describe how Oncoshot built a federated data platform on Amazon Web Services (AWS) to enable secure data exchange and connect industry experts with crucial insights derived from real-time patient data.

Founded in 1958, IITB has traversed a remarkable journey to emerge as one of the world's premier technical universities. With a steadfast commitment to engineering education and research, the institute has cultivated an outstanding faculty and alumni cohort globally recognised for their profound contributions.

CŌRE Diagnostics focuses on oncology, genomics, histopathology, and transplant immunology, offering consultative diagnostic reports that educate both physicians and patients. CŌRE Diagnostics is distinguished by its innovative approach, offering a second opinion on every test from its panel of specialised organ experts. The company stands out with its world-class group of specialists, ensuring that diagnostic reports are not just data but comprehensive insights.

Oncoshot, an innovative health insights exchange platform leveraging AI and federated learning, today announced it has forged a strategic partnership with Zhejiang Ablaze Medicine, a leading service provider of end-to-end clinical trial solutions, to jointly pioneer AI-led innovations to transform the speed, efficiency, accessibility of global drug development programs.

Oncoshot India is proud to announce a strategic partnership with Jaslok Hospital & Research Centre, one of the oldest and most esteemed super-speciality tertiary care hospitals in India. This partnership parallels Oncoshot India's cutting-edge real-time health insights exchange platform with Jaslok's rich legacy of providing comprehensive, compassionate, and patient-centred care.

Taipei Medical University (TMU) stands as a distinguished institution for medical education and research in Taiwan. This forward-thinking system aims to amplify inbound trial opportunities and establish a global presence through a platform for exchanging real-time insights, thereby assisting hospitals and research institutions in maintaining their leadership in clinical research through collaborative industry ventures. 

Especially for patients with advanced or aggressive cancers, time is of the essence. Without access to advanced tools or algorithms, patients may find it challenging to locate trials tailored to their unique medical profile. Recognising this, Oncoshot has developed Recommend Tx, a ground-breaking Large Language Model (LLM) AI feature that interprets free-text cancer information to match cancer patients with high-value clinical trials.

Japan presently ranks as the third-largest pharmaceutical market worldwide. This strategic partnership aims to synergise Buzzreach and Oncoshot’s complementary strengths to enhance various aspects of clinical trials, including feasibility assessments, participant screening, and enrolment throughout Japan.

'Singaporean healthtech leader, Oncoshot, has based its Australian headquarters in Melbourne, to leverage the city's world-leading cancer capability and hospital networks, making it the ideal location to support the company’s international growth.'

Susan's story shed light on the urgent need to constantly match clinical and genomic cancer data to the evolving landscape of clinical trials.

While the incidence of cancer in rural India is nearly half of that of urban India, the mortality rates are double due to the lack of adequate healthcare facilities, awareness about cancer and its risk factors, and limited access to cancer screening and treatment services.

Many cancer patients in India remain largely unaware of clinical trials. However, the recent infrastructural advancements in the local private hospitals make India an ideal platform for conducting clinical trials.

Earlier last year, Oncoshot India signed an MOU with the Basavatarakam Indo-American Cancer Hospital (BIACH) in May. The hospital’s objective is to serve the community and is run on a not-for-profit basis. It is a national-level healthcare institution specialising in cancer capabilities in research and education.

Our goal is to positively impact five million cancer patients globally, but we have recognised that we are also building a platform to support the development of tens, ideally hundreds, of drugs in the long term.

The awards celebrate the achievements of businesses and individuals who are leaders in their fields.

As a provider of clinical development services across all clinical trial phases and therapeutic areas, Novotech will leverage the Oncoshot platform to understand matching populations across key clinical trial markets in the APAC region.

Oncoshot has just announced one of its biggest collaborations to date with Icon Cancer Centre in Singapore, alongside Roche. Together the partners plan to facilitate more comprehensive genomic profiling data to increase access to more trial options for cancer patients.

Oncoshot has established a strategic partnership with Novartis to leverage its Project EISE platform which has the potential to enable more patients to access clinical trials in Singapore. EISE (pronounced as ‘easy’), an acronym for ‘Enhanced Clinical Trial Initiation, Screening and Enrolment,’ is a nationwide collaborative effort that connects cancer patients through an integrated, state-of-the-art care system.